Rademikibart Phase 2 asthma: FEV1 up 130mL (p=0.023); treatment failure down 66% (p=0.153)

Connect Biopharma Holdings Ltd

FEV1 at Day 7 improved 250 mL vs 120 mL placebo (130 mL delta, p=0.023), a statistically significant key secondary.
Treatment failure within 28 days reduced ~66% vs placebo but missed significance (p=0.153) due to lower-than-expected event rate.
ED/unscheduled visits for worsening asthma cut 50% vs placebo; safety comparable, 1 SAE rademikibart vs 3 placebo.
160 patients (79 rademikibart 600mg, 81 placebo); FDA Phase 3 alignment planned; COPD (CBP-201-207) data due later this month.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.